Dicerna Pharmaceuticals, Inc.
Extended dicer substrate agents and methods for the specific inhibition of gene expression

Last updated:

Abstract:

The invention provides compositions and methods for reducing expression of a target gene in a cell, involving contacting a cell with an isolated double stranded nucleic acid (dsNA) in an amount effective to reduce expression of a target gene in a cell. The dsNAs of the invention possess a single stranded extension (in most embodiments, the single stranded extension comprises at least one modified nucleotide and/or phosphate back bone modification). Such single stranded extended Dicer-substrate siRNAs (DsiRNAs) were demonstrated to be effective RNA inhibitory agents compared to corresponding double stranded DsiRNAs.

Status:
Grant
Type:

Utility

Filling date:

4 Jun 2021

Issue date:

14 Jun 2022